Objective: This preliminary open label study investigates the efficacy of a novel botanical-based supplement with anti-inflammatory and antioxidant properties as adjuvant therapy for chronic pain management. Recent research strongly identifies the roles of neuroinflammation, sensitization of the peripheral and central nervous system and oxidative stress as driving forces in the chronification of pain.
Current evidence identifies the role of PPAR (peroxisome proliferator–activated receptors) in pain pathways. Additionally, the endocannabinoid system (ECS) has gained recent attention for its role in the management of pain through various mechanisms. As such, evidence suggests the potential synergistic benefit of combining PPAR agonists, cannabinoids and antioxidants as a novel approach for treating chronic pain.
This supplement is directed at suppressing these driving forces in chronic pain with the inclusion of pan-PPAR (peroxisome proliferator–activated receptor) agonists that modulates key metabolic and inflammatory pathways, cannabinoids that act through the ECS and other botanical antioxidants and terpenes.
Because patients suffering from chronic pain frequently have co-morbid anxiety and insomnia, this study also investigates the potential benefits for reducing these two conditions. Finally, as many chronic pain patients are treated with opioids and/or medical marijuana products, the study also seeks to determine if the use of this supplement allows for a reduction in patient reliance on these two classes of medications.
The results of this open study determined that the majority (>90%) of the subjects reported significant benefits for pain, anxiety and/or sleep with minimal adverse effects. Additionally, many subjects also identified a reduced reliance on both their use of opioids and medical marijuana. This study strongly suggests significant benefits for the management of chronic pain and associated co-morbidities. Additional studies are warranted.
Abbreviations : 2-AG, 2-arachidonoyl-glycerol; AJA, ajulemic acid; CBD, cannabidiol; FAAH, fatty acid amide hydrolase; FABP, fatty acid binding protein; PEA, Opioid Analgesic Tolerance (OAT), Palmitoylethanolamide; THC, Δ9 -tetrahydrocannabinol; VCAM, vascular cell adhesion molecule.